Gina Columbus reports on FDA approvals in chronic myeloid leukemia, cutaneous T-cell lymphoma, cytomegalovirus infection, and a tumor assay, and clinical holds lifted from CAR T-cell therapy trials.

Providing us with insight into a trial not yet published, Pierluigi Porcu, MD, from Jefferson Hospital, Sidney Kimmel Cancer Center, Philadelphia, PN, discusses his team’s investigation into potential molecular biomarkers of response in mice induced to overexpress cytokine IL-15. Dr Porcu uses tipifarnib, a farnesyltransferase inhibitor which targets the RAS pathway, to treat the induced cutaneous T-cell lymphoma developed in the mice. Currently, he is focusing on looking for biomarkers of response from these animal trials. This video was recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX

Cutaneous lymphomas are cancers of lymphocytes that primarily involve the skin. Dr. Mark Fesler, board certified hematologist and oncologist at St. Luke's, discusses the disease and the ways St. Luke's collaborates with specialists for treatment.

Cutaneous lymphoma experts provide answers to the question: "Cutaneous B-Cell Lymphoma: What are the variants and how are they treated?"

#CTCL

Evangelina Papadavid, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses the impacts of the COVID-19 pandemic on the management and treatment of patients with cutaneous T-cell lymphoma (CTCL), in particular highlighting the impacts of postponing treatments. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

I am Passent a CTCL fighter. The video highlights the process of CTCL diagnosis.